ICER

Publications

Atopic Dermatitis:

Atopic Dermatitis: Final Report

Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis. J Drugs Dermatol. 2018;17(7):750-756.

Multiple Myeloma:

Multiple Myeloma: Final Evidence Report and Meeting Summary

Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapsed/refractory Multiple Myeloma in the U.S. Journal of Managed Care and Specialty Pharmacy 2018 Jan;24(1):29-38

 

Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapse/refractory multiple myeloma in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PCN107

Non-small Cell Lung Cancer:

Non-Small Cell Lung Cancer: Final Report

 

Multiple Sclerosis:

MS: Final Evidence Report and Meeting Summary

Multiple Sclerosis: Final Evidence Report

Brouwer E, Carlson JJ, Zimmermann M. Drug-specific discontinuation rates for available multiple sclerosis treatments. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND14

 

Strand L, Zimmermann M, Carlson JJ, Hansen RN. Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrom (CIS) from a United States (US) payer perspective. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND33

 

Zimmermann M, Brouwer E, Tice JA, et al. Cost-utility of disease modifying therapies for relapsing-remitting multiple sclerosis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND35

 

Osteoporosis:

Osteoporosis: Final Evidence Report

Psoriasis: 

Psoriasis Update: Final Report

Psoriasis: Final Evidence Report and Meeting Summary

Hendrix N, Ollendorf DA, CHapman R, et al. Cost-effectiveness of targeted therapy for moderate-to-severe plaque psoriasis: an analysis based on an institute for clinical and economic review (ICER) report. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PSS17

 

Inherited Retinal Disease:

Voretigene Neparvovec

Zimmermann M, Lubinga SJ, Banken R, et al. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value Health. 2019;22(2):161-167.

Hemophilia A:

Hemophilia A: Final Evidence Report

Hereditary Angioedema:

Hereditary Angioedema

Prostate Cancer:

Prostate Cancer: Final Report

Type II Diabetes:

Diabetes: Final Evidence Report and Meeting Summary